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Abstract: The Securinega alkaloids feature a compact 
tetracyclic structural framework and can be divided into four 
subclasses characterized by either a bridged [2.2.2]- or a [3.2.1]-
bicyclic core with two homologous series each. In the last two 
decades, many innovative strategies to chemically access the 
Securinega alkaloids have been developed. This review 
discusses selected structures and syntheses of representative 
members of the Securinega alkaloids. Ring-closing metathesis 
enabled the syntheses of securinine and norsecurinine, and 
different cycloaddition approaches were key to the syntheses of 
nirurine and virosaines A and B. Virosine A was accessed 
through a Vilsmeier-Haack/Mannich reaction cascade. A bio-
inspired vinylogous Mannich reaction allowed for the synthesis 
of allosecurinine and this strategy was extended by an 
intramolecular 1,6-addition to obtain bubbialidine and 
secu’amamine E. A rearrangement process of the latter two 
alkaloids furnished allonorsecurinine and allosecurinine, 
respectively. Finally, an expanded model for the biogenesis of 
the Securinega alkaloid subclasses is discussed. 
1. General Overview
Securinega alkaloids have fascinated chemists over decades. 
This obsession stems from to their large structural variety, their 
complex architecture, and their potent biological activity, which 
even resulted in clinical use. These facts triggered synthetic 
efforts of many research groups culminating in fascinating, 
efficient and instructive total syntheses of many Securinega 
alkaloids. The goal of this review is to introduce the reader to the 
structural complexity of these compounds, and to illustrate 
recent synthetic approaches towards their preparation. While 
this review is certainly not comprehensive, it may serve as an 
introductory overview to the field, and we refer the interested 
reader to excellent surveys that have been published in the 
past.[1] 
The Securinega alkaloids comprise a group of more than 60 
known natural products found in plants of the Phyllanthaceae 
family and more precisely in the Flueggea, Margaritaria, 
Phyllanthus and Securinega genera.[1] These plants are 
commonly found in the subtropical zones of the Americas, Africa 
and Asia, and are broadly applied as a traditional medicine in 
these regions. For example, the species Securinega suffruticosa 
and Flueggea virosa — two rich and well-studied sources of 
Securinega alkaloids — have been applied in Chinese folk 
medicine to treat a variety of symptoms such as lumbago, 
indigestion, impotence, rheumatism, infantile paralysis or 
eczema.[2] F. virosa served as a treatment for complications of 
the liver, kidneys, gall bladder, bladder and genitals as well as 
bilharzia in Senegalese medicine. In India, it was used against 
diabetes.[3] Margaritaria discoidea has been utilized in Guinean 
folk medicine to treat malaria, diabetes and diarrhea among 
others.[4] Phyllanthus niruri has been employed for the treatment 
of malaria and other diseases in India and China,[5] but also in 
Central Africa.[6] In West Africa, it served as a stomachic.[3,7] 
Several groups have reported on the isolation of Securinega 
alkaloids from samples of P. niruri collected in India[8] and 
Thailand.[9] However, these alkaloids were not found in samples 
of the same species collected in Brazil.[10] This result might be 
explained by the different environmental conditions presented to 
the plants. Recently, it was shown that plant growth regulators 
influence the alkaloid content of S. suffruticosa callus cultures, 
and promotion as well as inhibition of alkaloid production was 
observed.[11] To date, no report has been published on the 
isolation of Securinega alkaloids from a plant sample collected in 
the Americas. Interestingly, Securinega alkaloids have been 
obtained from Zygogynum pauciflorum,[12] a species of the 
Winteraceae family found in New Caledonia. Since this family is 
not related to Phyllanthaceae, the study revealed a rare case of 
metabolic convergence. The Phyllanthaceae family of plants 
represents one of several Euphorbiaceae segregates and was 
classified in 2006.[13] Nevertheless, the Securinega alkaloids are 
often assigned to the Euphorbiaceae in the recent literature. 
Figure 1. Two- and three-dimensional representations of securinine (1) and its 
stereoisomers. 
In 1956, securinine (1) was isolated from S. suffruticosa by 
Murav’eva and Ban’kovskii as the first member of this alkaloid 
family (Figure 1).[14] Being the most abundant and best-studied 
Securinega alkaloid, it has been the major representative ever 
since. The tetracyclic structure of securinine (1) was elucidated 
independently by two research groups in 1962[15] and the correct 
absolute configuration was established by chemical degradation 
studies[16] and an X-ray crystal structure of securinine 
hydrobromide.[17] Total synthesis of the racemic natural product 
and chiral resolution by recrystallization with (+)-10-
camphorsulfonic acid confirmed the structural and 
stereochemical assignments.[18] Another alkaloid isolated from S. 
suffruticosa showed similarities to securinine (1)[15b] and was 
identified as the epimeric allosecurinine (2), in which the A and B 
rings are fused with an opposite configuration.[19] Surprisingly, 
the investigation of the alkaloid contents of F. virosa 
(synonymous with S. virosa) yielded yet another stereoisomer of 
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securinine (1), which was found to be its enantiomer 
virosecurinine (3).[20] A systematic study of the two plant species 
and their metabolites then led to the last possible stereoisomer 
viroallosecurinine (4), the enantiomer of allosecurinine (2).[21] 
The study showed that while S. suffruticosa contained only 
securinine (1) and allosecurinine (2), S. virosa contained 
exclusively their optical antipodes virosecurinine (3) and 
viroallosecurinine (4). However, leaves of the male plant of S. 
suffruticosa var. amamiensis contained both securinine (1) and 
virosecurinine (3) along with allosecurinine (2).[21] Besides the 
very unusual distribution of stereoisomers, these observations 
also demonstrate the high diversity of alkaloid constituents in the 
different plants. 
Figure 2. The Securinega alkaloid skeletons and representative natural 
products of each class. 
The Securinega alkaloids can be divided into four groups based 
on their core structures (Figure 2). The compounds shown in 
Figure 1 share a securinane-type core, which is characterized by 
an azabicyclo[3.2.1]octane BC ring system with fused piperidine 
(A) and butenolide (D) rings. A homologous series of
norsecurinane-type structure contains a pyrrolidine instead of
the piperidine A ring; norsecurinine (5)[22] represents a member
of this class. In contrast to securinine (1), only two natural
stereoisomers of the lower homolog have been isolated, the
second one being ent-norsecurinine.[8b] The numbering for the
securinane and norsecurinane skeletons is identical except for
the C6 position being omitted for norsecurinane-type alkaloids.
Both groups comprise 14,15-dihydro derivatives with most of
them bearing 15-hydroxy or -methoxy substituents. Also,
numerous 4-hydroxy or -methoxy derivatives as well as
combinations of both (i.e. 4,15-disubstituted 14,15-dihydro
compounds) are known. The neosecurinane and
neonorsecurinane skeletons are characterized by an
azabicyclo[2.2.2]octane core with fused butenolide and either
piperidine or pyrrolidine rings. The neosecurinane-type alkaloid
securinol A (6) was isolated from S. suffruticosa in 1965 by Horii
and coworkers.[23] The Japanese researchers found that upon
treatment with methanesulfonyl chloride and pyridine the
compound was dehydrated to viroallosecurinine (4). Thus,
securinol A (6) was assigned a 15-hydroxy-14,15-
dihydrosecurinane-type structure. More than 25 years later,
Arbain, Sargent and coworkers investigated the alkaloid
contents of Margaritaria indica and revised the structure of
securinol A (6).[24] Based on a comparison of NMR data of 
alkaloid 6 and other Securinega alkaloids, and ultimately X-ray 
crystallographic analysis of securinol A hydrobromide, the 
neosecurinane-type structure shown in Figure 2 was established. 
Figure 3. Examples of Securinega alkaloids with unusual skeletons. 
Besides the four groups described so far, several alkaloids have 
been isolated possessing unprecedented structures, which do 
not fit the general motifs (Figure 3). Nirurine (8) was isolated 
from Phyllanthus niruri in 1986 by Cordell and coworkers, and its 
structure was elucidated by single crystal X-ray 
crystallography.[9] The pentacyclic compound has an additional 
oxazolidine ring formed by a C5-O-C8 bridge. Secu’amamine A 
(9), which was isolated from S. suffruticosa var. amamiensis in 
2003 by Ohsaki, Kobayashi and coworkers, contains an 
extended B ring and thus an azabicyclo[3.3.1]nonane core with 
an additional carbon atom between the C2 and C9 atoms.[25] Its 
structure was assigned using spectroscopic methods, mainly 
NMR analysis, and was later confirmed by comparison with 
material obtained through total synthesis.[26] Also, isolation of the 
C3-OH epimer secu’amamine H from F. suffruticosa 
(synonymous with S. suffruticosa) was reported by Wang, Ye 
and coworkers in 2014.[27] An extended B ring was also 
observed for phyllantidine (10), which was isolated from 
Phyllanthus discoides in 1965 by Munavalli and Parello.[28] 
Structural elucidation by Munavalli, Horii and coworkers was 
based on spectroscopic methods as well as the characterization 
of chemical degradation products of phyllanthidine.[29] This 
alkaloid features an oxazabicyclo[3.3.1]nonane core with an 
additional oxygen atom between the N and C7 atoms. 
Interestingly, this compound can be obtained from allosecurinine 
(2) by oxidation with hydrogen peroxide. The structure of
phyllantidine (10) was also confirmed by comparison with a fully
synthetic sample.[30] Arguably the most complex structures
among the monomeric Securinega alkaloids discovered so far
were reported for the pseudoenantiomeric virosaines A and B
(11), which were isolated from F. virosa by Zhang, Ye and
coworkers in 2012.[31] The three-dimensional structures of the
virosaines is best explained by starting from a
neonorsecurinane-type skeleton. The virosaines contain an
additional oxygen atom between the N and C7 atoms as well as
a bond between the C5 and C15 atoms. Their structures were
determined using a combination of NMR spectroscopic, circular
dichroism and X-ray crystallographic analyses, and were both
confirmed by comparison with material obtained by total
synthesis.[32,33]
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Figure 4. Examples of Securinega alkaloid dimers with different connectivity. 
A large group within the Securinega alkaloids, of which many 
were only discovered very recently, are oligomeric alkaloids. All 
known oligomers were isolated from F. virosa structurally 
spanning from dimeric to pentameric compounds.[1,34] The 
different dimers discovered so far display a large structural 
variety with respect to the modes of connectivity of the individual 
subunits (Figure 4). While most oligomers contain 
norsecurinane-type monomers (e.g. 12, 13), securinane- and 
neosecurinane-type subunits have been identified as well (e.g. 
14, 15). The larger oligomers are structurally less diverse and 
primarily feature norsecurinane-type monomers connected via 
C-C bonds between the C12, C14 and C15 atoms (16–19,
Figure 5). 
Figure 5. Examples of norsecurinine-based tetrameric Securinega alkaloids. 
Due to the great structural analogy between the different 
alkaloids and the plethora of stereoisomers present, the field of 
Securinega alkaloids can be confusing and several 
discrepancies and errors have found their way into the literature. 
For example, after the structural revision of securinol A (6) in 
1991,[24] it became obvious that several other known alkaloids 
like securinol B and C[23,35] or 14,15-dihydroallosecurinine-15β-
ol[36] needed or still need to be reinvestigated. Also, the 
controversial interpretation of analytical data during the 
structural elucidation of different alkaloids raises questions about 
the integrity of the results. For example, circular dichroism 
spectroscopy has frequently been used to determine the 
absolute configuration of previously unknown compounds. The 
spectra of newly isolated alkaloids were compared to those of 
known ones to draw conclusions on the similarities and 
differences in absolute configuration. But while one study 
attributed the observation of an opposite Cotton effect to an 
inverted configuration at the AB ring fusion at C2 of 
neonorsecurinane-type alkaloids,[37] another study concludes 
inverted configurations at C7 and C10 in the bridged BC ring 
system of neosecurinane-type alkaloids from the same 
observation.[38] These issues could raise some concern 
regarding the nature of both constitution and configuration for 
some alkaloids, in particular for those where no X-ray 
crystallographic studies addressing relative and absolute 
configuration have been conducted. Moreover, these structural 
questions call for total synthesis for clarification and verification  
of structure. These synthetic efforts will be discussed in the next 
section. 
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2. Total Synthesis of Securinega Alkaloids
Numerous synthetic studies on the Securinega alkaloids have 
been published and more than 20 publications reported the total 
synthesis of one or several members of the compound family 
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(Table 1).[39] Most approaches targeted the 
azabicyclo[3.2.1]octane-based alkaloids, such as securinine (1), 
norsecurinine (5), and their stereoisomers. But also different 
members featuring an azabicyclo[2.2.2]octane core such as 
nirurine (8),[40] virosine A[41] and bubbialidine[32] as well as 
compounds with an unusual structure like virosaines A[32] and B 
(11)[33] or flueggine A (12)[33,42] have been synthesized. While a 
number of innovative strategies have been developed for the 
construction of the tetracyclic Securinega alkaloid core, different 
motifs have reoccurred over time and certain transformations 
have proven exceptionally useful.  
REVIEW          
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Table 1. Total syntheses of Securinega alkaloids published to date in 
chronological order. 
Entry Authors Year Securinega alkaloid(s) Ref. 
1 Horii et al. 1967 Securinine (rac.) 18 
2 Heathcock et al. 1987 Norsecurinine (rac.) 43 
3 Jacobi et al. 1991 Norsecurinine, ent-
norsecurinine 
44 
4 Magnus et al. 1992 Norsecurinine (rac.), nirurine 
(rac.) 
40 
5 Weinreb et al. 2000 Norsecruinine, (+)-14,15-
dihydronorsecurinine 
59 
6 Honda et al. 2000 Securinine (rac., formal) 55 
7 Liras et al. 2001 Securinine (rac.) 45 
8 Honda et al. 2004 Viroallosecurinine 54 
9 Alibes, de March 
et al. 
2004 Securinine, (−)-
allonorsecurinine[a] 
51 
10 Honda et al. 2004 Securinine 53 
11 Figueredo et al. 2005 Norsecurinine 48 
12 Kerr et al. 2006 (+)-Phyllanthidine 30 
13 Weinreb et al. 2008 Secu’amamine A 26 
14 Busqué, de March 
et al. 
2008 Allosecurinine, 
viroallosecurinine 
57 
15 Kerr et al. 2008 Allosecurinine 47 
16 Thadani et al. 2009 Securinine 52 
17 Bayón, Figueredo 
et al. 
2009 Securinine, norsecurinine 49 
18 Wood et al. 2010 ent-Norsecurinine, (+)-
allonorsecurinine[a] 
46 
19 Srihari et al. 2012 (−)-Allonorsecurinine[a] 56 
20 Bélanger et al. 2012 Virosine A 41 
21 Wood et al. 2012 Securinine (rac.), 
allosecurinine (rac.) 
50 
22 Yang, Li et al. 2013 Virosaine B, flueggine A, 
(+)-allonorsecurinine,[a] 
norseucrinine 
33 
23 Gademann et al. 2013 Bubbialidine, virosaine A 32 
24 Yi, Jiang et al. 2014 Norsecurinine, (−)-niruroidine, 
flueggine A 
42 
25 Zheng et al. 2015 14,15-Dihydrosecurinine, 
securinine (formal) 
60 
26 Smith et al. 2015 Secu’amamine A 61 
27 Gademann et al. 2017 Secu’amamine E, bubbialine, 
allosecurinine, (+)- and (−)-
allonorsecurinine[a] 
67 
[a] Allonorsecurinine is a putative natural product that has not yet been 
isolated from a natural source. 
 
 
Scheme 1. The first total synthesis of racemic securinine (1) reported by Horii 
et al. in 1967. DBPO = dibenzoyl peroxide. 
The first total synthesis focused on securinine (1) and has been 
reported by Horii and coworkers in 1967,[18] right after their 
structural determination of the compound. The synthesis started 
with ketal 20, which was reacted with 2-pyridinyllithium (21); the 
two fragments representing the C and A rings of the final natural 
product, respectively (Scheme 1). The pyridine 22 was reduced 
by hydrogenation affording diastereoisomers and the ketal group 
was cleaved using hydrochloric acid. The amine was protected 
with acetic anhydride and both diastereoisomers were separated 
at this stage. By comparison with a degradation product of 
securinine (1) the major isomer was identified to possess the 
correct relative configuration and bromination afforded 
intermediate 23 in 14% yield. The olefinic double bond in the C 
ring was achieved by elimination of HBr and the D ring was 
installed by addition of lithium ethoxyacetylide followed by acidic 
REVIEW          
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hydrolysis. The acyl protecting group on the amine had to be 
exchanged to a more labile formyl group at this point affording 
the tricyclic intermediate 24. Final formation of the B ring was 
achieved applying an allylic 
bromination/deprotection/nucleophilic substitution sequence 
producing racemic securinine ((±)-1), although in low yield. 
Resolution of the enantiomers afforded pure securinine (1) and 
virosecurinine (3). 
 
Scheme 2. The first enantiospecific total synthesis of norsecurinine (5) 
reported by Jacobi et al. in 1991. 
After this seminal work, it took 20 years before the second total 
synthesis of a Securinega alkaloid was published by Heathcock 
and coworkers in 1987.[43] Starting from proline representing the 
A ring fragment, the B, C and D rings were constructed in this 
sequence in 12 linear steps affording racemic norsecurinine ((±)-
5) in 2% overall yield. The first enantioselective synthesis of 
norsecurinine (5) was reported by Jacobi and coworkers in 
1991,[44] who also utilized proline as a starting material (Scheme 
2). Starting from either L- or D-proline afforded the 
enantiomerically pure (+)- or (−)-norsecurinine (5), respectively. 
In this approach, proline served as the A ring fragment and was 
converted to oxazole 25, which underwent spontaneous Michael 
addition with enone 26 to generate labile intermediate 27. Upon 
attempted chromatography of intermediate 27, retro-Michael 
addition was observed. Tricycle 28 was obtained in 46% yield by 
heating of the crude substance leading to a Diels-Alder reaction 
between the oxazole and acetylene moieties under release of 
acetonitrile. The minor diastereoisomer could be separated and 
recycled by retro-Michael addition. Reduction of the keto group 
followed by dehydration formed the C ring double bond. The D 
ring was set up by desilylation and subsequent demethylation. 
Mesylation of the primary hydroxyl group gave intermediate 29. 
Final formation of the B ring was achieved by treatment with 
KHMDS leading to an intramolecular substitution reaction 
resulting in the natural product 5 in 69% yield. 
 
Scheme 3. Key cycloaddition step in the total synthesis of nirurine (8) reported 
by Magnus et al. in 1992. 
One year later, Magnus and coworkers reported the total 
synthesis of nirurine (8), the first synthetic study on a 
Securinega alkaloid with an azabicyclo[2.2.2]octane core 
(Scheme 3).[40] This synthesis also relies on a key Diels-Alder 
reaction to form the tetracyclic core skeleton. 3-Hydroxypyridine 
(30) was coupled with acid 31 to afford ester 32, which was 
transformed into diene 33 in one step. Desilylation using 
potassium fluoride in aqueous acetic acid presumably led to 
formation of allene 34. An intramolecular [4+2] cycloaddition 
produced intermediate 35 in 45% yield, which was further 
transformed into nirurine (8). 
 
Scheme 4. The total synthesis of racemic securinine ((±)-1) reported by Liras 
et al. in 2001. 
Within the first four decades after their discovery, only four 
studies on the total synthesis of Securinega alkaloids have been 
published. Since 2000, however, interest in the synthesis of 
these challenging natural products has increased tremendously 
and a variety of synthetic strategies have been developed. The 
total synthesis of racemic securinine ((±)-1) reported by Liras 
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and coworkers in 2001 (Scheme 4)[45] was pioneering in a sense 
in that it established several methodologies, which were 
frequently utilized in the syntheses published afterwards. 
Starting from silyloxyfuran 36, serving as the D ring precursor, 
addition to allyl bromide gave allylfuran 37 in good yield. 
Vinylogous Mannich reaction with an iminium species generated 
in situ from protected piperidine derivative 38 introduced the A 
ring (39). Addition of allyl phenyl sulfoxide (40) produced the 
intermediate 41, which was cyclized in a ring-closing metathesis 
(RCM) reaction using Grubbs’ first generation catalyst providing 
tricyclic intermediate 42. The double bond in the D ring was 
introduced by addition to phenylselenyl bromide and subsequent 
oxidation/elimination (43). Final formation of the B ring was 
achieved via acidic Boc deprotection followed by a 
dibromination/nucleophilic substitution/elimination sequence 
furnishing racemic securinine ((±)-1). This strategy is reminiscent 
of the allylic bromination/nucleophilic substitution sequence in 
the synthesis by Horii and coworkers (cf. Scheme 1) but distinct 
as it also leads to a net double bond isomerization. A similar 
approach has been used by Wood and coworkers in their 2010 
total synthesis of (+)-allonorsecurinine.[46] 
 
Scheme 5. Diastereoselective total synthesis of securinine (1) reported by 
Honda et al. in 2004. 
The synthesis by Liras and coworkers exemplified the utility of 
RCM in the construction of the tetracyclic Securinega alkaloid 
frameworks and several other groups have used this 
transformation in their syntheses. While several approaches 
have adopted RCM for the formation of the C ring as seen 
above,[30,40,47,48,49,50] there are also examples of D ring formations 
accomplished by this technique.[51,52] An impressive one-step 
C/D ring formation approach via tandem RCM in the first 
stereoselective total synthesis of securinine has been reported 
by Honda and coworkers in 2004 (Scheme 5).[53] Starting from 
known R-pipecolic acid-derived thioester 44 unsaturated side-
chains were introduced sequentially by addition of (Z)-3-
hexenylmagnesium bromide (45) to the thioester followed by 
addition of TMS acetylene to the ketone and desilylation to give 
enyne 47 in excellent yield. Alkylation of the hydroxyl function 
using allyl trichloroacetimidate (48) affording dienyne 49 set up 
the stage for the key tandem RCM reaction using the ruthenium 
catalyst 50 to construct the C/D ring system in one step and high 
yield (51). Attempts to use an acrylate ester instead of allyl ether 
49 in this transformation were unsuccessful and thus allylic 
oxidation with chromium trioxide and 3,5-dimethylpyrazole (52) 
was applied to form the butenolide 53. Final B ring formation 
was accomplished using the 
bromination/deprotection/substitution sequence originally 
developed by Horii and coworkers. A similar strategy has been 
applied in the total synthesis of viroallosecurinine (4) reported in 
a follow-up publication by Honda and coworkers in 2004.[54] 
 
Scheme 6. Tandem RCM in the synthesis of norsecurinine (5) reported by 
Yang, Li et al. in 2013. 
This tandem RCM strategy was later picked up by Yang, Li and 
coworkers in their total syntheses of virosaine B (11) and 
flueggine A (12) published in 2013,[33] which proceeded via 
norsecurinine (5) and (+)-allonorsecurinine as intermediates. In 
this report, commercially available Weinreb amide 54 was 
converted into intermediate 55 in an alkylation sequence very 
similar to the one described above (Scheme 6). The use of relay 
RCM with catalyst 56 facilitated tandem enyne metathesis on 
the α,β-unsaturated ester 55 allowing for the direct formation of 
the butenolide moiety obviating an additional oxidation step. 
Again, B ring formation of tricyclic intermediate 57 was 
accomplished using the sequence by Horii and coworkers 
affording norsecurinine (5) in this case. Interestingly, this 
sequence became increasingly popular and many groups 
reported on its use in the recent years.[42,51,55,56] 
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Scheme 7. Total synthesis of norsecurinine (5) reported by Figueredo et al. in 
2005. 
Application of the vinylogous Mannich reaction to connect A and 
D ring fragments, which was pioneered by Liras and coworkers 
(cf. Scheme 4), was also implemented by other research groups. 
In the total synthesis of norsecurinine (5) reported by Figueredo 
and coworkers in 2005 (Scheme 7),[48] this transformation was 
used to prepare RCM precursor 58. Succinimide (59) was 
converted into hydroxylactam 60 in three steps. Exposure to 
boron trifluoride etherate lead to formation of the corresponding 
N-acyliminium ion, which was captured with silyloxyfuran 61 to 
form product 58. Cyclization by RCM followed by reduction of 
the lactam and desilylation gave known intermediate 62. 
Following the mesylation/nucleophilic substitution sequence 
developed by Jacobi and coworkers (cf. Scheme 2) yielded 
norsecurinine (5). This approach has also been applied in the 
total synthesis of securinine (1) reported by the same group in 
2009.[49]  
 
Scheme 8. Total synthesis of allosecurinine (2) starting from the natural 
product (+)-menisdaurilide ((+)-63) reported by Busqué, de March et al. in 
2008. 
The same group reported another strategy involving a key 
vinylogous Mannich reaction in 2008.[57] Their synthesis 
commenced from the natural product (+)-menisdaurilide ((+)-63), 
the synthesis of which they had reported before,[58] and a 
possible biogenetic relevance of the key transformation was 
suggested. After protection of (+)-menisdaurilide ((+)-63), a one-
pot procedure including formation of a silyloxyfuran from 
butenolide 64 followed by vinylogous Mannich reaction with an 
N-acyliminium ion afforded intermediate 65 (Scheme 8). The N-
acyliminium ion was generated in situ from lactamol 66 by Lewis 
acid activation using dibutylboron triflate. Only two 
chromatographically separable diastereoisomers were formed in 
this transformation in a ratio of 4:1 with the major isomer 67 
possessing the desired absolute configuration. The synthesis 
was completed by desilylation followed by mesylation to create a 
leaving group. Acidic Boc cleavage and subsequent 
intramolecular substitution furnished allosecurinine (2). The 
same synthetic route was applied using (−)-menisdaurilide ((−)-
63) providing viroallosecurinine (4). 
 
Scheme 9. Recent approach to the tricyclic core of Securinega alkaloids using 
NHC catalysis by Snyder et al. and an extension of the methodology 
employing a hetero-Pauson-Khand reaction by Porée et al. 
Beside the frequently reoccurring synthetic motifs described so 
far other interesting methods have enriched the diversity of 
Securinega alkaloid total synthesis. For example, the studies on 
butenolide D ring formation by Horner-Wadsworth-Emmons 
reaction or a related one-pot procedure applying the Bestmann 
ylide during the total syntheses of norsecurinine (5), (+)-14,15-
dihydronorsecurinine and phyllanthine by Weinreb and 
coworkers,[59] which have been picked up during the recent total 
synthesis of 14,15-dihydrosecurinine by Zheng and 
coworkers.[60] Also the intramolecular aza-Michael addition/aldol 
addition/lactonization sequence developed by Weinreb and 
coworkers for the construction of secu’amamine A from a linear 
precursor should be mentioned at this point.[26] Smith and 
coworkers synthesized this alkaloid using anion relay 
chemistry.[61] Another unique approach toward the bridged B/C/D 
ring system of securinine was recently reported by Snyder and 
coworkers (Scheme 9).[62] By an intramolecular N-heterocyclic 
carbene (NHC)-catalyzed [3+2] cycloaddition using catalyst 
precursor 68 in the presence of titanium isopropoxide, the ynal 
and keto functions of compound 69 were cyclized in a single 
step to yield the protected Securinega alkaloid core 70 in 31%. 
Inspired by this work, Porée and coworkers have developed a 
[2+2+1] cycloaddition approach featuring a hetero-Pauson-
Khand reaction.[63] Thus, the precursor 71 carries a terminal 
alkyne and the missing C1 unit is introduced by metal-bound 
carbon monoxide. Although the product 70 was obtained in only 
50% yield, this transformation seems highly valuable for the 
development of further synthetic strategies toward the 
Securinega alkaloid family. 
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3. The Total Syntheses of Bubbialidine and 
Virosaine A 
In 2013, our research group has published the first 
enantioselective total syntheses of the neosecurinane-type 
alkaloid bubbialidine (72) and the unusual birdcage-shaped 
virosaine A (73),[32] which were both accessed by the synthetic 
route outlined in the following. A key intermediate of the 
synthesis is the butenolide 74, which represents the C and D 
rings in the final natural product and is the TBDPS-protected 
form of the natural product (+)-aquilegiolide. The route to 
compound 74 was based on related synthetic studies reported in 
the literature.[57,64] Initially the synthesis was designed to yield 
virosaine A (73), which had been isolated from F. virosa in 2012 
by Wang, Zhang, Ye and coworkers.[31] Bubbialidine (72) was 
obtained by deprotection of an intermediate en route. 
 
Scheme 10. Synthesis of the bicyclic key intermediate 74. 
The synthesis commenced with a mono-epoxidation of 
commercially available 1,4-cyclohexadiene (75) with meta-
chloroperbenzoic acid (mCPBA) followed by epoxide opening 
using cyanomethyllithium (Scheme 10). The resulting secondary 
alcohol was acetylated with acetic anhydride giving the racemic 
acetate 76 in 22% yield. Kinetic resolution by an enzyme was 
applied in the synthesis and alcohol 77 was obtained in 95% 
enantiomeric excess. Basic hydrolysis of the nitrile function and 
subsequent acid-catalyzed lactone formation gave compound 79 
in 80% yield.[64a] The D ring double bond was introduced by an 
α-selenation/oxidative elimination sequence affording the 
butenolide 80 in a moderate yield of 48%. Diastereoselective 
introduction of the hydroxyl group and concomitant isomerization 
of the C-C double bond into conjugation with the butenolide 
moiety was achieved through epoxidation using mCPBA 
followed by regioselective epoxide opening using potassium 
carbonate. Protection with TBDPSCl afforded the intermediate 
74 in 50% yield. 
 
Scheme 11. Construction of the bridged tetracyclic framework and synthesis 
of bubbialidine (72). 
The A ring pyrrolidine fragment was introduced by a vinylogous 
Mannich reaction applying the one-pot procedure developed by 
Busqué, de March and coworkers (Scheme 11).[57] The reaction 
afforded an excellent yield of 90% and only two out of four 
possible diastereoisomers were formed and could be separated 
chromatographically giving compound 82. While the original 
publication reported a diastereoisomeric ratio of 4:1 in favor of 
the desired isomer using a homologous 6-membered lactamol, 
the present transformation proceeded without any 
diastereoselectivity. The Boc group was removed by acidic 
treatment affording the corresponding hydrochloride salt 83. 
Under extremely mild conditions using dipotassium hydrogen 
phosphate as a base, intramolecular vinylogous aza-Michael 
addition occurred producing the bridged tetracycle 84 in a very 
good yield of 86% over the two steps. Desilylation of this 
intermediate using Olah’s reagent led to the natural product 
bubbialidine (72) in 92% yield. 
 
Scheme 12. Final steps in the total synthesis of virosaine A (73). 
Moving on toward the second natural product, intermediate 84 
was oxidized to the corresponding N-oxide using mCPBA 
(Scheme 12). Cope elimination was observed upon exposure to 
silica opening up the B ring to give hydroxylamine 85. Oxidation 
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to the nitrone 86 with N-tert-butylbenzenesulfinimidoyl chloride 
(87) in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) proceeded regioselectively and a spontaneous 
intramolecular 1,3-dipolar cycloaddition furnished the unusual 
alkaloid framework. Final desilylation using tetrabutylammonium 
fluoride (TBAF) produced the natural product virosaine A (73) in 
81% yield. In an independent effort, Yang, Li and coworkers 
have prepared the pseudoenantiomeric virosaine B (11) from 
(+)-allonorsecurinine using a very similar oxidation/1,3-dipolar 
cycloaddition sequence.[33] (+)-Allonorsecurinine, on the other 
hand, was accessed by the tandem RCM strategy outlined in 
Scheme 6. 
4. Secu’amamine E and its Enantiomer 
Virosine A 
In continuation of the synthetic program on Securinega alkaloids 
within our research group, we turned our focus on 
neosecurinane-type alkaloid secu’amamine E (88), which was 
isolated alongside secu’amamines F and G from Securinega 
suffruticosa var. amamiensis by Ohsaki and coworkers in 
2009.[65] Their structures were elucidated by spectroscopic 
means (mainly NMR spectroscopy) and the absolute 
configuration of their B/C ring systems was determined to be 
opposite to securinol A (6) by a comparison of the respective 
circular dichroism (CD) spectra showing an opposite Cotton 
effect. Thus, secu’amamine E (88, Figure 6) constitutes the 
higher homolog of bubbialidine (72) and represented an 
attractive target for total synthesis, as it should be obtainable 
using a similar synthetic strategy. No detailed investigations 
concerning the bioactivity of secu’amamine E (88) have been 
reported. The isolation paper states in a short comment at the 
end of the publication that no cytotoxicity on P388 leukemia cells 
was observed. 
 
Figure 6. Structures of different neosecurinane-type alkaloids. 
Another neosecurinane-type alkaloid isolated from Flueggea 
virosa by Ye and coworkers in 2008 is virosine A (89), the 
optical antipode of secu’amamine E (88).[38] Its structure and 
absolute configuration were determined using the same 
techniques mentioned above and no investigations concerning 
the bioactivity of this alkaloid have been reported. The structure 
of virosine A (88) was confirmed via total synthesis of the natural 
product by Bélanger and coworkers in 2012.[41] Due to the 
enantiomeric relationship between virosine A (89) and 
secu’amamine E (88), which has not been pointed out in any of 
the mentioned literature reports, the key features of the 
synthesis by Bélanger and coworkers shall be presented at this 
point. 
 
Scheme 13. Enantioselective total synthesis of virosine A (89) reported by 
Bélanger et al. in 2012. 
The synthesis started from meso-epoxide 90, which was 
elaborated into intermediate 91 in 46% overall yield via 
chromium-catalyzed desymmetrization using 
azidotrimethylsilane, hydroxyl-directed epoxidation followed by 
silyl protection and subsequent epoxide opening with diethyl-
phosphonoacetic acid (Scheme 13). The hydroxyl function was 
oxidized using Dess-Martin periodinane (DMP) and treatment 
with potassium tert-butoxide triggered an intramolecular Horner-
Wadsworth-Emmons reaction to obtain butenolide 92 
representing the C/D ring system of the final natural product. 
The azide group was then reduced and the resulting amine was 
alkylated and formylated sequentially using 3-butynyl tosylate 
(93) and N-formylbenzotriazole (95), respectively. Silylation of 
the butenolide moiety afforded silyloxyfuran 96 in 49% yield from 
azide 92. The key transformation of the synthesis was a 
Vilsmeier-Haack/Mannich cyclization cascade leading to the 
bridged tetracyclic core structure, a method that had been 
reported by the same group in 2008.[66] Activation of the formyl 
group using triflic anhydride and 2,6-di-tert-butyl-4-
methylpyridine (DTBMP) led to a Vilsmeier-Haack reaction with 
the silyloxyfuran moiety. The resulting iminium species then 
reacted with the terminal alkyne function in a Mannich reaction 
upon addition of tetrabutylphosphonium bromide giving 
tetracycle 97 in 58% yield. Cleavage of the bromide, reduction of 
the A ring by hydrogenation and final desilylation of the hydroxyl 
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group provided virosine A (89) in 46% yield. In summary, the 
natural product 89 was obtained by a sequence of 13 linear 
steps in 3.4% overall yield from meso-epoxide 90. 
5. The First Total Synthesis of Secu’amamine 
E[67] 
 
Scheme 14. Synthesis of key intermediate 74. 
Our synthesis of secu’amamine E (88) started with the 
preparation of the chiral hydroxyenone 98 and an efficient route 
to this compound starting from mono-ketal 99 was developed by 
Hayashi and coworkers during the total synthesis of (+)-
panepophenanthrin.[68] Alcohol 98 was then protected as a silyl 
ether  (100, Scheme 14) and a mixture of compound 100 and 
oxaziridine 101 was treated with NaHMDS to obtain the desired 
α-hydroxy ketone 102 as a single diastereoisomer. When crude 
compound 102 was heated in presence of the Bestmann ylide 
(103)[69] 43% yield of the key intermediate 74 were obtained in a 
diastereoisomeric ratio of 3.3:1. This attractive strategy had 
been applied by Weinreb and coworkers for the late stage D ring 
formation in their synthesis of (+)-14,15-dihydronorsecurinine.[59] 
Compared to our original synthesis of butenolide 74 (cf. Scheme 
10) the overall yield could thus be improved by a factor of ten. 
 
Scheme 15. Synthesis of secu’amamine E (88). 
Due to the structural similarity between secu’amamine E (88) 
and bubbialidine (72) we planned to adopt the remaining steps 
from our total synthesis of the latter alkaloid. Using the 
methodology described by Busqué, de March and coworkers[57] 
butenolide 74 was converted into the silyloxyfuran 104 (Scheme 
15). Since the configuration of the butenolide moiety is given up 
during this step, the starting material could be utilized as a 
diastereoisomeric mixture. Addition of dibutylboron triflate to a 
mixture of silyloxyfuran 104 and lactamol 66 triggered formation 
of an N-acyliminium ion followed by Mannich addition affording a 
mixture of two diastereoisomers in a ratio of 4.3:1 and the major 
isomer 65 was isolated in 69% yield. The Boc group was 
removed using ethereal hydrogen chloride solution and 
hydrochloride 105 was then subjected to an intramolecular 
vinylogous aza-Michael addition to close the bridging B ring and 
form the azabicyclo[2.2.2]octane core 106 of the natural product 
in 81% yield. Final desilylation produced secu’amamine E (88) in 
an excellent yield of 98%. Thus, the total synthesis of 
secu’amamine E (88) was achieved in 12 synthetic steps from 
commercially available ketal 99 in an overall yield of 8.5%. We 
investigated the ecotoxicity of secu’amamine E (88) in an assay 
against Thamnocephalus platyurus (beaver-tail fairy shrimp). No 
toxic effects were observed in concentrations up to 100 µM 
confirming the findings by Ohsaki and coworkers.[65]  
6. Rearrangements of Neo(nor)securinane- to 
(Nor)securinane-type Alkaloids 
The transformation of an azabicyclo[2.2.2]octane core into an 
azabicyclo[3.2.1]octane core observed by Magnus and 
coworkers during the total synthesis of nirurine (8) might be of 
great significance for the biosynthesis of the Securinega 
alkaloids.[40] Although Horii and coworkers also reported similar 
transformations for securinol A (6),[23] B and C,[35] the correct 
structural foundation had not been established and recognized 
at the time. Follow-up work corrected the misassginment and 
validated the underlying transformations.[24] As a consequence, 
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these observations have not been considered during the 
development of the general biosynthetic pathway formulated in 
the 1970s.[70] The observations by Magnus and coworkers did 
not receive much attention in the literature. The only similar 
transformation reported to date is the rearrangement of 
niruroidine (107) to norsecurinine (5, Scheme 16).[42] However, a 
closer look at the reported substrates reveals that niruroidine 
(107) represents the (−)-enantiomer of the racemic synthetic 
intermediate reported by Magnus and coworkers. 
 
Scheme 16. Rearrangement reported by Ye, Jiang et al. 
With synthetic access to secu’amamine E (88) we decided to 
investigate the generality of the dehydrative rearrangement of 
neo(nor)securinane- to (nor)securinane-type alkaloids (Scheme 
17). Synthetic bubbialidine (72) was obtained through the 
previously published route[32] and bubbialine (107) was prepared 
from the second diastereoisomer of intermediate 82. Thus, three 
different alkaloids were tested. When secu’amamine E (88) was 
treated with methanesulfonyl chloride in the presence of DMAP 
and triethylamine, very fast conversion of the substrate was 
observed and allosecurinine (2) was obtained in a yield of 93% 
(Scheme 17A). Although reactions were typically run for 10–15 
min, complete consumption of the alkaloid 88 within the first 
minute was observed by TLC. Very similar results were obtained 
with the homologous bubbialidine (72, Scheme 17B). A fast 
spot-to-spot transformation proceeded and (−)-allonorsecurinine 
((−)-111) was isolated, albeit in a somewhat lower yield of 63%. 
When bubbialine (108) was treated under the same conditions, 
again, fast spot-to-spot transformation was observed (Scheme 
17C). However, bubbialine mesylate 112 was isolated in almost 
quantitative yield. Only under forcing conditions (100 °C, 
microwave, 6 h) rearrangement of this intermediate was 
observed and afforded (+)-allonorsecurinine ((+)-111) in a low 
yield of 21% and only in moderate purity. 
 
Scheme 17. Dehydrative rearrangement of Securinega alkaloids. 
The results of these experiments agree with the proposed 
mechanism of the rearrangement process. The configuration at 
C2 appears to have no influence on the transformation when 
compared to the results of Magnus et al. For the decreased yield 
of (−)-allonorsecurinine ((−)-111) compared to allosecurinine (2) 
two reasons were considered. On one hand, a loss of material 
during purification by flash chromatography cannot be excluded. 
On the other hand, norsecurinine (5) is known to be a reactive 
compound and the large variety of known norsecurinine-based 
oligomers is a result and testimony thereof. While decomposition 
of the synthetic allosecurinine (2) upon storage at 4 °C was 
observed within several days to a few weeks, the decomposition 
of both allonorsecurinine enantiomers (+)- and (−)-111 appeared 
to be faster. Also, the clean transformation observed by TLC 
analysis of the reaction mixture did not indicate undesired side 
reactions. The stability of the mesylate intermediate 112 
obtained from bubbialine (108) can be explained by the 
synperiplanar configuration of the amine and ester groups. While 
the antiperiplanar configuration of the other two alkaloids allows 
for an intramolecular SN2 reaction leading to an aziridinium 
intermediate (109, 110), this is not possible with mesylate 112. 
The lone pair of the nucleophilic amine group cannot donate 
electron density into the σ* orbital of the C-O bond and thus the 
mesylate needs to be extruded via an SN1 mechanism. The high 
temperatures required for the SN1 reaction probably led to 
undesired side reactions as well as decomposition of (+)-allonor-
securinine ((+)-111). Hence, a low yield of impure product (+)-
111 was obtained. 
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7. A Refined Hypothesis for the Biogenesis of 
Securinega Alkaloids 
 
Scheme 18. Linear biogenetic hypothesis for allosecurinine (2). 
The results presented above support the hypothesis that a 
dehydrative rearrangement of neo(nor)securinane-type alkaloids 
with an azabicyclo[2.2.2]octane core to (nor)securinane-type 
alkaloids featuring an azabicyclo[3.2.1]octane core is involved in 
the biogenesis of Securinega alkaloids. Based on these findings 
with reports on earlier biogenetic steps described in the literature, 
experimental support for a refined model for the biogenesis of 
these alkaloids is presented: A linear biosynthetic pathway for 
these compounds (Scheme 18). In the 1970s, plant feeding 
experiments using radioactively labeled compounds showed that 
Securinega alkaloids are derived from tyrosine and lysine 
catabolites.[70] Furthermore, the asymmetric incorporation of 
lysine retaining the ε-nitrogen atom via cadaverine and Δ1-
piperideine intermediates was demonstrated.[70f] According to the 
hypothesis of Busqué, de March and coworkers tyrosine would 
be metabolized into the CD ring fragment, which, in the case of 
allosecurinine (2), is represented by (+)-menisdaurilide ((+)-63) 
or (+)-aquilegiolide. The lysine-derived A ring fragment would be 
introduced in a net vinylogous Mannich reaction to give 
intermediate 113. The amino group would then attack the 
unsaturated lactone moiety in an intramolecular 1,6-addition to 
furnish the neosecurinane-type secu’amamine E (88). 
Dehydrative rearrangement of alkaloid 88 through the 
aziridinium ion 109 would forge the securinane-type 
allosecurinine (2). Thus, we hypothesize that the 
neo(nor)securinane alkaloids possessing a [2.2.2]-bicyclic core 
are direct biosynthetic precursors of the (nor)securinane 
alkaloids featuring a [3.2.1] core. However, this hypothesis 
raises new questions about the family of Securinega alkaloids, 
some of which might be addressed through further phyto-
chemical investigations of the plants producing these 
compounds. Since the rearrangement favorably proceeds with 
alkaloids featuring an antiperiplanar configuration of the amine 
and hydroxyl groups, the fate of the syn-configured congeners 
remains unclear. These alkaloids were not reported to 
accumulate in plants and isomerization at the C15 position to 
invert the orientation of the hydroxyl function might occur in 
nature. A linear biogenesis implies a connection between certain 
alkaloid members and should allow for a prediction, which 
compounds should occur in the same plant. For example, every 
plant that contains secu’amamine E (88) should also contain 
allosecurinine (2) due to the hypothetical biogenetic relationship 
outlined herein. Accordingly, every plant that contains 
bubbialidine (72) should also contain (−)-allonorsecurinine ((−)-
111). So far, neither enantiomer of allonorsecurinine (111) has 
been isolated from a natural source. Therefore, isolation of 
either compound would corroborate the linear biogenetic 
hypothesis outlined herein. Furthermore, a general detailed 
mapping of the occurrence of the different alkaloids and their 
relative amounts would help in understanding their 
interrelationships. 
8. Conclusion 
The Securinega alkaloids represent a fascinating family of plant 
natural products with bridged tetracyclic structures exhibiting 
interesting bioactivities. Although the compounds are generally 
small and compact, the myriad of known stereoisomers and 
representatives featuring unique variations of the common 
backbone generates a diverse group of alkaloids. After being 
overlooked for more than 20 years, the synthetic community 
rediscovered the Securinega alkaloids as challenging targets for 
total synthesis and, especially during the last two decades, 
numerous remarkable strategies have been developed to 
access these substances chemically. Several studies have 
contributed to the formulation of a biosynthetic pathway and 
future phytochemical investigations may provide additional 
insights on the origin and the chemistry of these natural products. 
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REVIEW 
Securinega alkaloids display a wealth 
of fascinating structures combined 
with powerful bioactivities. Efficient 
synthetic strategies towards these 
natural products have been developed 
to prepare them in synthetic form. 
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